We describe the assembly of a cationic lipid-nucleic acid nanoparticle from a liquid monophase containing water and a water miscible organic solvent where both lipid and DNA components are separately soluble prior to their combination. Upon removal of the organic solvent, stable and homogenously sized (70-100 nm) lipid-nucleic acid nanoparticles (Genospherest) were formed. The low accessibility (o15%) of the nanoparticle-encapsulated DNA to a DNA intercalating dye indicated well-protected nucleic acids and high DNA incorporation efficiencies. It was demonstrated that Genospheres could be stably stored under a variety of conditions including a lyophilized state where no appreciable increase in particle size or DNA accessibility was observed following reconstitution.
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We describe the assembly of a cationic lipid-nucleic acid nanoparticle from a liquid monophase containing water and a water miscible organic solvent where both lipid and DNA components are separately soluble prior to their combination. Upon removal of the organic solvent, stable and homogenously sized (70-100 nm) lipid-nucleic acid nanoparticles (Genospherest) were formed. The low accessibility (o15%) of the nanoparticle-encapsulated DNA to a DNA intercalating dye indicated well-protected nucleic acids and high DNA incorporation efficiencies. It was demonstrated that Genospheres could be stably stored under a variety of conditions including a lyophilized state where no appreciable increase in particle size or DNA accessibility was observed following reconstitution.
Finally, Genospheres were made target-specific by insertion of an antibody-lipopolymer (anti-HER2 scFv (F5)-PEG-DSPE) conjugate into the particle. The target specificity (4100-fold) in HER2 overexpressing SK-BR-3 breast cancer cells was dependent on the degree of PEGylation, where the incorporation of high amounts of PEG-lipid on the particle surface (up to 5 mol%) had only a minor effect on the transfection activity of the targeted Genospheres. In summary, this work describes a novel, readily scalable method for preparing highly stable immunotargeted nucleic acid delivery vehicles capable of achieving a high degree of specific transfection activity. Gene Therapy (2006) 13, 646-651. doi:10.1038/sj.gt.3302699; published online 8 December 2005 Keywords: nonviral gene delivery; plasmid encapsulation; targeted gene delivery; HER2 receptor Synthetic nonviral gene delivery vehicles offer the advantages of relatively easy preparation, lower toxicity and less expensive components in comparison with viral-based delivery methods. One common nonviral gene therapy delivery system is lipid mediated, usually assembled from mixtures of cationic liposomes and DNA (lipoplex). This method was first described in 1987 by Felgner et al., 1 and up to July 2005 8.6% of worldwide clinical trials in gene therapy use this protocol or variations of it. 2 The relatively high positive charge, combined with a polymorphic lipid component, helps make these complexes efficient delivery vehicles in vitro, where the binding to cells is primarily electrostatic in nature and colloidal stability and target specificity are less of a concern than for delivery in vivo.
In contrast, the effectiveness of lipoplexes for targeted gene delivery in vivo has been disappointing. 3 It is known that their high cationic charge density aids their rapid clearance from circulation by the reticuloendothelial system and their tendency to form large aggregates enhances accumulation in the microvasculature of 'first pass' organs such as the spleen, liver and particularly the lungs. 4, 5 Newer procedures for encapsulating DNA have been developed, which produce small colloidally stable particles that have shown remarkable improvements in their pharmacokinetic characteristics in comparison to early lipoplexes. These procedures generally rely on assembly of the particles through steps involving precondensing DNA, 6 liquid-liquid phase separations and sonication, 7 extrusion, 8 rehydration of a dried complex previously extracted from an organic solvent, 9 the presence of detergents [10] [11] [12] or liposomal entrapment of nucleic acid. 13 We suggested that formation of DNA-lipid particles could also be facilitated under such conditions where both lipid and DNA were molecularly or micellarly soluble prior to their combination. The concentration range of the organic solvent used to prepare these particles was chosen on the basis of the ability of the aqueous/organic solvent monophase to independently solubilize the nucleic acid and the lipid component before combination. For example, it is known that DNAcationic surfactant complexes become soluble in aqueous/ethanol mixtures above 40% (v/v) ethanol 14 and that DNA precipitates in mixtures containing high concentrations of ethanol. Therefore, it was interesting to us to study the particles formed in intermediate ethanol concentrations where both DNA and lipid components were soluble prior to combination. Under these conditions, interactions between DNA and cationic lipids would be improved, eliminating the major bilayer structural rearrangements that occur when DNA interacts with cationic liposomes. 15 In the present work, we describe this new method and the resulting nucleic acidlipid nanoparticles were termed Genospherest.
A typical composition was a cationic lipid dioctadecyldimethylammonium bromide (DDAB), or 1,2-dioleoyl-3-trimethylammonio)propane (DOTAP), a phosphatidylcholine (e.g. 1-palmitoyl-2-oleoyl phosphatidylcholine-POPC), cholesterol (Chol), and plasmid DNA in a ratio of 6:15 4 À ratio from 1.67 to 2. As the majority of the preparations have a 7 ratio of 2, we will only state the charge ratio where it differs from this value.
Genospheres were prepared as follows; cationic and neutral lipids were combined in 100% ethanol (Gold Shield Chemical Co., Hayward, CA, USA) and diluted with an equal volume of 5 mM HEPES, pH 7.4. Plasmid DNA from a stock solution (2 mg/ml in Tris-EDTA buffer, pH 8.0) was placed into a separate tube and the volume adjusted typically to that of the lipid solution volume with 5 mM HEPES, pH 7.4 and ethanol to a final concentration of 50% (v/v). Both tubes were placed in a water bath at 601C and once thermally equilibrated, the DNA solution was added rapidly to the lipid solution, pipetting gently up and down 4-5 times to ensure complete mixing. The mixture was allowed to attain room temperature, and ethanol was removed by rotary evaporation or dialysis against unbuffered 144 mM NaCl. For ligand directed targeting studies, HER2-targeted Genospheres were prepared by incubation of Genospheres with F5-cys-mal-PEG(2000)-DSPE antibody conjugate in saline overnight at 371C. 16 Typically, an amount of conjugate equal to 15 mg antibody was added per mmol of POPC in the sample. The antibody conjugate is presented in a solution also containing a proportion of cysteine quenched maleimide-PEG-DSPE 17 and therefore nontargeted control samples were heated in the same manner using an equivalent amount of additional PEG-DSPE. Genosphere samples were stored at 41C until use.
The volume-weighted size distribution of the resulting particles was measured by dynamic light scattering (DLS), and they displayed an average size of 70-110 nm with a polydispersity in the range of 20-35 nm. Freeze-fracture electron microscopy (FFEM) was also used to characterize the size, shape, and polydispersity of Genosphere particles. The FFEM photographs indicated that the average size of Genospheres after ethanol removal was approximately 100 nm ( Figure 1a ) and the large number of similarly sized spherical particles observed per FFEM photograph indicates the uniformity of the particles. A FFEM micrograph taken of a Genosphere sample obtained after purification on a sucrose gradient ( Figure 1b) shows their uniformity and similar size distribution to that seen before purification. This indicates that the particles formed initially following removal of ethanol from the bulk mixture, corresponded to true cationic lipid/nucleic acid particles and the observed structures are not simply empty lipid vesicles. The smooth fracture plane in the majority of the structures is indicative of the particles having a bilayer structure. In addition, DNA in these particles was well Figure 1 Freeze-fracture electron micrographs (FFEM) of Genospheres. Genosphere samples were analyzed by FFEM before (a) and after (b) purification on a sucrose gradient. Sample aliquots (200 ml) of Genospheres or HBS, pH 6.5 buffer (control) were carefully applied to the top of a 0-15% (w/w) sucrose gradient and the tubes ultra-centrifuged at 192 000 g for 10 h at 221C (Ultracentrifuge L8-70M, Beckman) using an SW50.1 rotor. After centrifugation, aliquots (150 ml) were removed from each tube and in the case of the Genosphere containing tubes, the turbid fraction analyzed by FFEM. The samples were cooled rapidly in liquid propane using the sandwich technique (410 4 k/sec). The fixed specimens were fractured and shadowed with Pt/C in a Balzers BAF 400D freezefracture device at À1201C and 2 Â 10 À6 Torr and the cleaned replicas subsequently examined by transmission electron microscopy using a Zeiss CEM 902A electron microscope. The particles consisted of DDAB/POPC/Chol/PEG-DSPE (6/6/12/0.12) nmol:nmol:nmol: nmol per mg DNA). Scale bars represent 100 nm in both pictures. All dialkyl lipids were purchased from Avanti Polar lipids (Alabaster, AL, USA) while Chol was purchased from Calbiochem (San Diego, CA, USA). Plasmid DNA (pCMV/luc + ) was prepared using an EndoFree Plasmid Giga kit (Qiagen, Chatsworth, CA, USA) from competent Escherichia coli amplified in LB medium. Plasmid concentration was determined by absorbance at 260 nm (e ¼ 6600 l mol À1 cm
À1
) and purity by calculating the ratio A 260 nm /A 280 nm (Shimadzu, UV160U). DNA was considered to be sufficiently protein free with A 260 nm /A 280 nm ratio of at least 1.85. Particle size was also measured by DLS (Nicomp C370 Particle Size Analyzer).
Genospheres ME Hayes et al protected from the surrounding medium, as determined from low Picogreen intercalating dye binding (o10%, see Figure 2b ), therefore, we assume that DNA resides within the particle core.
The stability of a gene carrier against DNA degradation, particle aggregation and/or dissociation in plasma is an absolute requirement for in vivo delivery success. The stability of Genospheres against these processes was characterized ex vivo by measuring changes in size, DNA dye accessibility and susceptibility to DNase I digestion following incubation in 50% (v/v) human plasma (Figure 2a-c, respectively) . The effect of PEGylation on the plasma stability of Genospheres was investigated by preparing Genospheres with 0.5-5 mol% PEG-DSPE (of cationic lipid and POPC content). The initial sizes of these particles was o100 nm, and the initial dye accessibility was approximately 6%, indicating highly protected DNA. Exposure to 50% (v/v) human plasma resulted in an increase in size over the duration of the study. However, the increase in size was reduced by inclusion of PEG-DSPE. The sample with 0.5 mol% PEG-DSPE exhibited a large increase in size, up to 1 mm. The more highly PEGylated samples (2-5 mol%) also increased in size, to 400 nm, where they remained for up to 24 h. For the Genospheres with a high neutral lipid content (15 nmol of POPC and 10 nmol Chol per mg DNA), the dye accessibility remained below 20% over 24 h. However, the sample with lower neutral lipid content showed higher instability, with approximately 40% dye accessibility over the same period. These results indicate that both PEGylation and the relative neutral lipid content affect Genosphere stability in the presence of plasma. The differences in stability may result from incomplete neutral lipid coverage, or possibly the reduced cationic charge density with higher neutral lipid content reducing protein binding. The resistance of PEGylated Genospheres to extensive aggregation in human plasma is likely to be an important characteristic of these particles with regard to potential in vivo utility.
Using an identical formulation, Genospheres and lipoplexes were prepared and tested for their susceptibility to DNase I digestion (Figure 2c ). The Genospheres were also incubated with human plasma for 24 h at 371C Figure 2 The effect of human plasma on Genosphere particle size (a), DNA dye accessibility (b) and DNase I digestion sensitivity (c).
Genosphere particles (320 mg/ml DNA) with varying PEG-DSPE (N-(o-methoxy-(poly(oxyethylene)-a-oxycarbonyl))-1,2-distearoyl-3-sn-phospatidylcholine) content were incubated with equal volume human plasma at 371C. The formulations consisted of DOTAP/ POPC/Chol (nmol/nmol/nmol) per mg DNA in the ratios (~) 6/15/10; (') 6/15/10; (J) 5/15/10 (7 ¼ 1.67), (*) 6/12/8 and (D) 6/15/10 with 0.5, 2, 4, 4 and 5% PEG-DSPE respectively. At intervals, aliquots (200 ml) were removed and free plasma separated by size exclusion chromatography using Sepharose CL-2B preequilibrated with HBS, pH 6.5 and were analyzed for size (DLS) and DNA dye accessibility, by using a fluorescent high affinity DNA binding molecule, Picogreen (Molecular Probes, Eugene, OR, USA). Dye accessibility assays were performed by measuring the fluorescence intensity ratio between nondissociated particle samples and dissociated (solubilized) particles samples. The total amount of DNA was quantified from the fluorescence intensity of the dissociated particle samples using the concurrently run standard curve, performed in quadruplicate using microplate fluorometer (FL-600A, Bio-Tek Instruments Inc., Winooski, VT, USA) equipped with 485/20 nm bandpass excitation filter and 530/ 25 nm bandpass emission filter. Agarose gel electrophoresis of DNA isolated from Genospheres and lipoplex that had the formulation DOTAP/POPC/Chol/PEG-DSG (6/15/10/0.62 nmol/nmol/nmol/ nmol per mg DNA) was performed in similar manner as described previously 12 except that 30 U DNase I (deoxyribonuclease I, type II obtained from Sigma (St Louis, MO, USA)) was incubated with 20 mg DNA at 371C for 1.5 h and after the phenol/chloroform extraction, no precipitation step was used. Simply the same volume of each DNA solution (approximately containing 250 ng DNA) was mixed with a loading buffer (0.25% (w/w) bromophenol blue, 40% (w/w) sucrose) and subjected to agarose gel electrophoresis. A 0.8% agarose gel was used, and the electrophoretic details and staining procedures described elsewhere.
12 PEG-DSG denotes 1-monomethoxypolyethyleneglycol-2,3-distearoylglycerol (PEG 2000 ). Lanes 1 and 10 contain the 1 kbp DNA ladder (Biolabs, NE, USA), lanes 2 and 3 are DNA isolated from lipoplex in the absence and presence and of DNase I, respectively. Lanes 4 and 5 contain DNA isolated from Genospheres that were incubated with 50% (v/v) human plasma for 24 h at 371C in the presence and absence of DNase I, respectively, likewise lanes 6 and 7 contain DNA isolated from Genospheres incubated with and without DNase I. Naked plasmid DNA that was incubated in the absence (lane 8) and presence (lane 9) of DNase I were run as controls.
Genospheres ME Hayes et al prior to the digestion assay to determine if plasma could alter the integrity of the Genosphere. From an agarose gel electrophoresis study of the isolated DNA, we observed that DNase I causes degradation of naked DNA, giving rise to a DNA smear (lane 9). In contrast, Genospheres treated with DNase I or incubated with plasma and then treated with DNase I give a similar band appearance to untreated plasmid DNA (lane 8). However, it is noticeable that the lipoplex formulation did not protect the DNA very well from digestion with changes in the band migration pattern and the appearance of a smear. The Picogreen dye accessibility measurements of Genospheres, lipoplexes and plasma treated Genospheres were 1170.2, 73.071.7 and 25.071.1%, respectively.
The Smoluchowski zeta potential was calculated from electrophoretic measurements made using BeckmanCoulter Delsa 440-SX. 18 Measurements were made in 5 mM HEPES, 5% (w/w) sucrose, pH 7.4. The zeta potential of a typical Genosphere formulation containing DOTAP/POPC/Chol (6/15/10 nmol/nmol/nmol) per mg DNA was found to have a value of +45.6 mV, indicating they are cationic in nature. This fact, along with the low dye accessibility (highly protected DNA) and evidence of a bilayer containing particle (Figure 1 ) strengthens our assumption that the majority of the particles contain charged neutralized DNA in the core, with the excess cationic lipid and neutral lipid forming one or more bilayers around it.
The stability of Genospheres during storage was determined in terms of changes in mean size and dye accessibility, wherein the degree of increase in particle size or dye accessibility reflected instability and loss of particle integrity. Three storage conditions were studied: (i) Genospheres in low ionic aqueous buffer, with added tonicity agents, refrigerated at 4-61C or (ii) frozen at À801C and (iii) Genospheres lyophilized in the presence of a cryoprotectant and a buffer substance, stored lyophilized at 4-61C and reconstituted in water prior to measurements (Table 1 ). All three conditions resulted in very small changes in the apparent size of the particles. The degree of dye accessibility following storage under these conditions remained low, close to the value obtained for freshly prepared particles, and suggests that Genospheres can be stably stored under any of these conditions.
Successful in vivo gene therapy will require a combination of a stable carrier and an effective selective targeting approach. Examples where ligand-directed targeting provided increases in transfection efficiency are present in the literature. [19] [20] [21] [22] We combined Genospheres with a highly internalizable anti-HER2 scFv 0 fragment (F5) 23 covalently attached to the PEG terminus of an amphiphilic PEG-lipid derivative by a previously described membrane capture method. 24, 25 This allows for selective gene targeting to the human breast cancer cell line SK-BR-3, which overexpresses the HER2/neu receptor. The transfection activity of anti-HER2 immunoGenospheres, as well as the original nontargeted Genospheres, in HER2-overexpressing SK-BR3 cells was studied (Figure 3 ). The Genosphere transfection activity was substantially enhanced by the addition of the targeting antibody. In particular, the specificity of activity increased by a factor of 13-116-fold with increasing PEG-DSPE content. With targeting, the transfection activity was rather independent of the amount of PEGylated lipids present in the formulation, suggesting that ligand-specific targeting overcomes the PEG-related inhibition of the particle-cell association. As controls, Figure 3 Luciferase expression in SK-BR-3 cells following incubation with Genospheres. The formulation used was DOTAP/POPC/ Chol (6/15/10) (nmol lipid per mg DNA) with varying amounts of PEG-DSPE. Targeted and nontargeted Genospheres are represented by hatched and filled bars, respectively. As controls, a lipoplex formulation consisting of DOTAP/DOPE (12/12 nmol/nmol/mg DNA, 7 ¼ 4/1) was prepared aseptically and naked plasmid DNA were included in the study. HER2-overexpressing human breast adenocarcinoma cells SKBR-3 cells (ATT, Rockland, MD, USA) were cultured in McCoy's 5A medium supplemented with 10% (v/v) fetal bovine serum, 100 mg/ml of streptomycin sulfate and 100 U/ml of penicillin G at 371C, (UCSF Cell Culture Facility, San Francisco) with 5% CO 2 . The cells were plated at a density of 250 000 cells per well in a 12-well plate (Corning) and acclimated overnight. The final media volume in each well was 1 ml and each well received 1 mg of pCMV/luc + in the form of (i) free DNA, (ii) simple plasmid/ liposome complexes or (iii) Genosphere preparations. All plasmid preparations were incubated with the cells for 6 h, removed by aspiration following washing with Hank's buffered saline (2 Â 1 ml), and the incubation continued for another 18 h following the addition of fresh media (1 ml). The amount of lux reporter gene expression was characterized by the amount of luciferase in the cell lysates determined by luminometry (Monolight 3010, Analytical Luminescence Laboratory) and was expressed in ng luciferase per mg of cell lysate protein as described previously. Genosphere of composition DDAB/POPC/Chol/PEG-DSPE (6/15/ 10/0.21 nmol/nmol/nmol/nmol/mg plasmid DNA) was prepared as described above, with ethanol removal facilitated by dialysis against 5 mM HEPES, pH 7.4. The storage conditions employed were refrigerated at 41C, frozen at -801C and lyophilized. After storage for 1 week, samples were brought to room temperature or reconstituted with deionized water, and size and dye accessibility measurements performed as described. Although Genospheres may not be optimal for in vitro use, as the absolute transfection efficiency of the targeted Genospheres was lower that the non-PEGylated lipoplex formulation, the optimal design of an in vivo formulation, will benefit from inclusion of a certain degree of PEGylation to potentially improve pharmacokinetic properties and reduce nonspecific transfection in nontarget organs. PEG-DSPE was shown previously to inhibit transfection of non-targeted lipoplexes in a PEG-DSPE dose dependent manner. 26 We have previously shown that by conjugation of an anti-HER2 Fab 0 to the distal termini of PEG (2000)-DSPE containing liposomes, the inhibitory effect of PEG (2000)-DSPE on cell binding and uptake of liposomes by HER2 overexpressing cells is essentially avoided up to a PEG-DSPE content as high as 5.7 mol% of total lipid. 27 For Genospheres used in these transfection studies, we observed greater anti-HER-2 specificity at higher PEG(2000)-DSPE content. This is essentially due to the decrease in nonspecific binding at higher PEG derivative content. However, quite unexpectedly, the transfection activity at higher PEG-DSPE concentrations of Genospheres was not severely reduced (Figure 3) , implying that Genospheres targeted with F5-PEG(2000)-DSPE remain highly internalizable and active at high PEGlipid content, an important consideration in view of potential in vivo applications. This in contrast to the observations made by Song et al. 28 who used galactose-PEG-DSPE as a targeting ligand and observed a striking dependence of transfection efficiency on the molecular weight of the PEG moiety, with PEG molecular weights 41450 essentially completely inhibiting transfection activity of the nanoparticles.
Recently, Jeffs et al. 13 have developed a procedure that allows for efficient DNA encapsulation, producing small particles that have long circulating properties (plasma half-life of 13 h) and importantly have shown persistent anti-hepatitis B virus activity in vivo. 29 They quickly combine an ethanolic lipid solution with an aqueous DNA solution in a T-shaped mixing chamber so that ethanol-destabilized liposomes spontaneously form thereby entrapping the nucleic acid with efficiencies ranging from 60 to 70%. A second mixing step that further reduces the ethanol content increases the encapsulation efficiency to 80-90%.
To our knowledge, the Genosphere methodology is unique in the sense that DNA and lipid are combined in an environment that precludes lipid condensed phases, thereby enhancing the potential for unhindered chargecharge interactions. This is achieved by simply heating the lipid and DNA separately in the same organic/ aqueous monophase above the lipid solubility temperature and ensures that upon mixing no preformed lipid condensed phases are present and the components are not exposed to local areas of variable solvent concentrations. It is a one-pot process with essentially two wellscalable operations, temperature controlled solution mixing and ethanol removal.
We have described a procedure for making nucleic acid-lipid nanoparticles that are relatively small in size and can be easily stored under a variety of conditions. We have also demonstrated that PEGylation can reduce the levels of aggregation of these cationic Genospheres in human plasma and that they selectively target and transfect HER2 overexpressing cells in vitro without loss of activity at higher PEG-lipid content, which may be important for future targeted in vivo use.
